Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Non-cash Items (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Non-cash Items for 7 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-cash Items rose 9.14% to $5.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.8 million, a 9.14% increase, with the full-year FY2025 number at $5.8 million, up 34.32% from a year prior.
  • Non-cash Items was $5.8 million for Q4 2025 at Fulcrum Therapeutics, down from $5.9 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $35.1 million in Q1 2024 to a low of $150489.0 in Q1 2025.
  • A 5-year average of $7.0 million and a median of $4.7 million in 2024 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: soared 1293.41% in 2021, then crashed 99.57% in 2025.
  • Fulcrum Therapeutics' Non-cash Items stood at $27.1 million in 2021, then crashed by 93.04% to $1.9 million in 2022, then surged by 701.74% to $15.1 million in 2023, then crashed by 64.58% to $5.4 million in 2024, then grew by 9.14% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Non-cash Items are $5.8 million (Q4 2025), $5.9 million (Q3 2025), and $5.4 million (Q2 2025).